成纤维细胞激活蛋白是肿瘤分子成像和治疗的一个有前途的靶点。研究表明，成纤维细胞激活蛋白抑制剂（FAPI）放射性示踪剂在评估各种癌症类型（包括胰腺癌（PC））方面优于 18F-FDG PET/CT。因此，我们进行本次荟萃分析，以评价分析68Ga/18F-FAPI与18F-FDG在PC中的差异，为FAPI PET成像的临床应用提供证据。在目前的荟萃分析中，原创研究使用放射性标记的 FAPI 作为诊断放射性示踪剂对截至 2024 年 1 月 1 日发布的数据进行了分析，并与 PC 中 PET 的 18F-FDG 进行了比较。检索的数据库包括 pubmed 和 web of science，检索的主题词包括 PC 和 FAPI。入组研究的质量通过诊断准确性研究2的质量评估进行评估，并使用R语言进行荟萃分析。共有7项研究，包括322名患者，比较了FAPI PET成像和18F-FDG PET/ PC 中的 CT。总体而言，FAPI PET 成像显示出更高的汇总敏感性（0.99 [95% CI: 0.97-1.00] vs. 0.84 [95% CI: 0.70-0.92]）和曲线下面积（0.99 [95% CI: 0.98-1.00] vs. . 比 18F-FDG PET/CT 低 0.91 [95% CI: 0.88-0.93])。证据表明，FAPI PET 成像在对原发肿瘤、淋巴结转移和远处转移的综合敏感性方面优于 18F-FDG。此外，与 18F-FDG 相比，FAPI PET 成像改善了 25% 的 PC 患者的 TNM 分期，并改变了 11.7% 的 PC 患者的临床治疗。 FAPI PET 成像在原发性 PC、淋巴结和淋巴结的检测方面优于 18F-FDG。远处转移、TNM 分期和临床管理。版权所有 © 2024 大学放射科医生协会。由爱思唯尔公司出版。保留所有权利。

Fibroblast activating protein is a promising target for tumor molecular imaging and therapy. Studies showed that fibroblast activating protein inhibitor (FAPI) radioactive tracers presented superiority over 18F-FDG PET/CT in the evaluation of various cancer types, including pancreatic cancer (PC). Therefore, we conducted this meta-analysis to evaluate and analyze the differences between 68Ga/18F-FAPI and 18F-FDG in PC, in order to provide evidence for the clinical application of FAPI PET imaging.In the current meta-analysis, original studies published as of January 1, 2024 were analyzed using radiolabeled FAPI as a diagnostic radioactive tracer and compared to 18F-FDG for PET in PC. Databases searched included pubmed and web of science, and subject headings searched included PC and FAPI. The quality of the enrolled studies was evaluated by Quality Assessment of Diagnostic Accuracy Studies 2, and the meta-analysis was conducted using R language.A total of seven studies including 322 patients compared the diagnostic performance of FAPI PET imaging and 18F-FDG PET/CT in PC. Overall, FAPI PET imaging showed higher pooled sensitivity (0.99 [95% CI: 0.97-1.00] vs. 0.84 [95% CI: 0.70-0.92]) and area under the curve (0.99 [95% CI: 0.98-1.00] vs. 0.91 [95% CI: 0.88-0.93]) than 18F-FDG PET/CT. The evidence showed that FAPI PET imaging is superior to 18F-FDG in pooled sensitivity to primary tumor, lymph node metastasis, and distant metastasis. Moreover, FAPI PET imaging improved TNM staging in 25% of PC patients and changed clinical management in 11.7% of PC patients compared to 18F-FDG.FAPI PET imaging is superior to that of 18F-FDG in the detection of primary PC, nodal and distant metastases, TNM staging and clinical management.Copyright © 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.